Holen Sie sich die Stockscreener-App
13.88
5.55%
0.73
Handel nachbörslich:
14.00
0.12
+0.86%
Schlusskurs vom Vortag:
$13.15
Offen:
$13.31
24-Stunden-Volumen:
196.83K
Relative Volume:
0.89
Marktkapitalisierung:
$531.39M
Einnahmen:
$25.42M
Nettoeinkommen (Verlust:
$-143.75M
KGV:
-3.999
EPS:
-3.4709
Netto-Cashflow:
$-129.55M
1W Leistung:
+17.93%
1M Leistung:
+10.33%
6M Leistung:
+134.46%
1J Leistung:
+74.81%
1-Tages-Spanne:
$13.10
$14.00
1-Wochen-Bereich:
$12.11
$14.00
52-Wochen-Spanne:
$4.93
$14.00
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
13.88 | 503.44M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says - marketscreener.com
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - marketbeat.com
Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - marketscreener.com
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - marketbeat.com
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - stocktitan.net
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - stocktitan.net
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - marketbeat.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - marketbeat.com
Big Picture: Can Entrada Therapeutics Inc deliver consistent EPS growthTrade Analysis Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
Hedge Fund Bets: Can Entrada Therapeutics Inc outperform under higher oil prices2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - stocktitan.net
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
Gainers Report: Can Entrada Therapeutics Inc ride the EV wave2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc benefiting from innovation trends2026 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug EndMonth: How does Entrada Therapeutics Inc compare to its peersPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Trading Recap: Will Entrada Therapeutics Inc benefit from rising consumer demandGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
Harmony Biosciences (NASDAQ:HRMY) and Entrada Therapeutics (NASDAQ:TRDA) Critical Review - Defense World
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares - MarketBeat
Understanding the Setup: (TRDA) and Scalable Risk - Stock Traders Daily
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year HighTime to Buy? - MarketBeat
[144] Entrada Therapeutics, Inc. SEC Filing - Stock Titan
Aug Breakouts: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Gainers & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Volume: How does Entrada Therapeutics Inc compare to its peersJuly 2025 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (TRDA) CFO executes planned stock sale - Stock Titan
Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA - MarketBeat
HC Wainwright Has Optimistic Outlook of TRDA Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for TRDA Earnings - MarketBeat
TRDA SEC FilingsEntrada Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Form 144: TRDA insider sales — Kory Wentworth sold 8,651 shares (TRDA) - Stock Titan
TRDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):